# AB Science

Source: https://onco.cc/companies/ab-science/  
OnCo record `ab-science` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AB Science is a Paris biotechnology company built around masitinib, an oral tyrosine kinase inhibitor aimed at mast cells and macrophages that it has tested in phase 3 trials across cancers and neurological diseases.

## Summary

AB Science, listed on Euronext Paris, develops masitinib, an oral tyrosine kinase inhibitor that acts on KIT, LYN and other kinases in mast cells and macrophages. The company has run a long series of phase 3 trials with masitinib in cancers including pancreatic cancer, prostate cancer, mastocytosis and gastrointestinal stromal tumours, and in amyotrophic lateral sclerosis, multiple sclerosis and Alzheimer's disease, and has faced repeated regulatory setbacks; the drug is not approved for cancer in the United States or the European Union. It appears on OnCo as one of the most active industry sponsors of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: AB Science S.A.
- Tags: ctgov-sponsor
- HQ: Paris
- Type: biotech
- Website: https://www.ab-science.com

## Sources

- Official website: https://www.ab-science.com
- ClinicalTrials.gov: trials led by AB Science: https://clinicaltrials.gov/search?lead=AB%20Science
- Wikipedia: https://en.wikipedia.org/wiki/AB_Science

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)

---
JSON: https://onco.cc/api/v1/entities/ab-science.json